Belimumab inhibits B cell proliferation by blocking the binding of soluble B-lymphocyte stimulator (BLyS) to B cell receptors and is the world’s first approved biologic for the treatment of SLE. The gene discussed is TNFSF13B; the disease is systemic lupus erythematosus.